AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2289995 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylaxis
Number of subjects: 114
Study 394563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromocriptine (5 mg dd for 14 days)
Number of subjects: 90
Study 394563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stilbestrol (15 mg dd for 5 days)
Number of subjects: 90
Study 394563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic compound (bendroflumethazide 15 mg dd for 5 days)
Number of subjects: 90
Study 394563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of estradiol (10 mg) and testosterone (200 mg) esters administered immediately after delivery
Number of subjects: 90
Study 394563 — intervention group
Group type: COMPARATOR
Intervention: Physical methods (breast support and local infra-red waves)
Number of subjects: 90
Study 31791393 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscription journals
Number of subjects: 268
Study 31791393 — intervention group
Group type: COMPARATOR
Intervention: Open access journals
Number of subjects: 268
Study 27682207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-management program (PSM)
Number of subjects: 141
Study 27682207 — intervention group
Group type: COMPARATOR
Intervention: Exercise-attention control (EAC)
Number of subjects: 141
Study 25853511 — intervention group
Group type: EXPERIMENTAL
Intervention: MCH handbook implementation
Number of subjects: 501
Study 25853511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MCH handbook)
Number of subjects: 501
Study 25853511 — intervention group
Group type: EXPERIMENTAL
Intervention: MCH handbook usage
Number of subjects: 501
Study 23421781 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg daily)
Number of subjects: 170
Study 23421781 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin-clavulanate (22.5 mg/kg twice daily)
Number of subjects: 170
Study 21878810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment with ketamine
Number of subjects: 10
Study 21878810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment with morphine
Number of subjects: 10
Study 21878810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21878810 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 21878810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neuropathic pain
Number of subjects: 10
Study 19669886 — intervention group
Group type: EXPERIMENTAL
Intervention: Computeen program (preventive technology and psychosocial skills development)
Number of subjects: 55
Study 17848673 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 90
Study 17848673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15549976 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 20
Study 15549976 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 20
Study 11905957 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil diet (80 g corn oil/d)
Number of subjects: 28
Study 11905957 — intervention group
Group type: COMPARATOR
Intervention: Mixed oil diet (68 g olive oil and 12 g sunflower oil/d)
Number of subjects: 28
Study 9591764 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3171
Study 9591764 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 3171
Study 8176569 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 80
Study 3067654 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg bromocriptine at bedtime
Number of subjects: 6
Study 3067654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29663320 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-to-implant breast reconstruction with acellular dermal matrix (ADM)
Number of subjects: 59
Study 28068857 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 241
Study 28068857 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 241
Study 28068857 — intervention group
Group type: COMPARATOR
Intervention: Placebo + standard of care (SOC)
Number of subjects: 241
Study 26486928 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide combined with diphenhydramine
Number of subjects: 884
Study 26486928 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide combined with diphenhydramine and dexamethasone
Number of subjects: 884
Study 26486928 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide alone
Number of subjects: 884
Study 26486928 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 884
Study 26486928 — intervention group
Group type: EXPERIMENTAL
Intervention: valproate
Number of subjects: 884
Study 26486928 — intervention group
Group type: EXPERIMENTAL
Intervention: Any medication regimen
Number of subjects: 884
Study 24125149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 14
Study 19939587 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride (SEL, 5mg bid, n=51)
Number of subjects: 101
Study 19939587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLO, n=50)
Number of subjects: 101
Study 18591906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (manual and electroacupuncture)
Number of subjects: 68
Study 18591906 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 68
Study 18591906 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (manual and electroacupuncture) and Non-penetrating sham acupuncture
Number of subjects: 68
Study 16909787 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for TBE meningitis
Number of subjects: 40
Study 16909787 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for neuroborreliosis
Number of subjects: 40
Study 16909787 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 14659772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0
Study 10966942 — intervention group
Group type: EXPERIMENTAL
Intervention: National Eye Care Programme (NECP) interventions
Number of subjects: 1169000
Study 8792380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 15
Study 8792380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 15
Study 8792380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1482871 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted interventions (various types including reminder, feedback, dose planning, patient education, medical record)
Number of subjects: 106
Study 1482871 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 106
Study 4036844 — intervention group
Group type: EXPERIMENTAL
Intervention: minimal-carbohydrate diet (800 kcal; 58% protein and 42% fat by weight)
Number of subjects: 20
Study 4036844 — intervention group
Group type: EXPERIMENTAL
Intervention: carbohydrate-supplemented diet (1,000 kcal; 42% protein, 30% fat, and 28% carbohydrate)
Number of subjects: 20
Study 4036844 — intervention group
Group type: COMPARATOR
Intervention: minimal-carbohydrate diet
Number of subjects: 20
Study 4036844 — intervention group
Group type: COMPARATOR
Intervention: carbohydrate-supplemented diet
Number of subjects: 20
Study 31248950 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 1.25 mg/d
Number of subjects: 365
Study 31248950 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 2.5 mg/d
Number of subjects: 365
Study 31248950 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 5 mg/d
Number of subjects: 365
Study 31248950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 28586239 — intervention group
Group type: EXPERIMENTAL
Intervention: kiR urban version of the curriculum
Number of subjects: 1464
Study 28586239 — intervention group
Group type: EXPERIMENTAL
Intervention: kiR rural version of the curriculum
Number of subjects: 1464
Study 27115376 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 SQ‐HDM
Number of subjects: 834
Study 27115376 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SQ‐HDM
Number of subjects: 834
Study 27115376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 24502414 — intervention group
Group type: EXPERIMENTAL
Intervention: customary treatment plus active physiotherapy
Number of subjects: 200
Study 24502414 — intervention group
Group type: COMPARATOR
Intervention: customary treatment (information and advice on a specialist clinic)
Number of subjects: 200
Study 22191494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrostomy tract infiltration with bupivacaine
Number of subjects: 60
Study 22191494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 60
Study 21058474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and medication (Thiamazole and Euthyrox)
Number of subjects: 52
Study 21058474 — intervention group
Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 52
Study 17652834 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 124
Study 17652834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 16188135 — intervention group
Group type: EXPERIMENTAL
Intervention: sapylin + cisplatin (DDP)
Number of subjects: 60
Study 16188135 — intervention group
Group type: COMPARATOR
Intervention: cisplatin alone (DDP)
Number of subjects: 60
Study 12422105 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length sequential EPC devices (EPC)
Number of subjects: 45
Study 12422105 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin injections (HEP)
Number of subjects: 45
Study 12422105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (HEP+EPC)
Number of subjects: 45
Study 10600289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife excision (n = 38)
Number of subjects: 66
Study 10600289 — intervention group
Group type: COMPARATOR
Intervention: Loop excision (n = 28)
Number of subjects: 66
Study 8949824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg and dimethindene 0.1 mg kg‐1 (H1 blocker)
Number of subjects: 24
Study 8949824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2038996 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (1000 mg daily for 7 days)
Number of subjects: 61
Study 2038996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3900 mg daily for 7 days)
Number of subjects: 61
Study 6215443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study 6215443 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine
Number of subjects: 30
Study 6215443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drug groups
Number of subjects: 30
Study 30796199 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-dexamethasone (Kd56)
Number of subjects: 911
Study 30796199 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib-dexamethasone (Vd)
Number of subjects: 911
Study 29420600 — intervention group
Group type: EXPERIMENTAL
Intervention: +50% precipitation treatment
Number of subjects: 0
Study 29420600 — intervention group
Group type: EXPERIMENTAL
Intervention: +33% precipitation treatment
Number of subjects: 0
Study 29420600 — intervention group
Group type: EXPERIMENTAL
Intervention: -50% precipitation treatment
Number of subjects: 0
Study 29420600 — intervention group
Group type: EXPERIMENTAL
Intervention: -33% precipitation treatment
Number of subjects: 0
Study 29420600 — intervention group
Group type: COMPARATOR
Intervention: Ambient precipitation treatment
Number of subjects: 0
Study 27044272 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant flooring (2.54 cm SmartCells)
Number of subjects: 150
Study 27044272 — intervention group
Group type: COMPARATOR
Intervention: Control flooring (2.54 cm plywood)
Number of subjects: 150
Study 25244777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganfule prescription combined with chemotherapy
Number of subjects: 58
Study 25244777 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 58
Study 22307494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral essential amino acids (EAAs) 8 g/d for 2 months
Number of subjects: 125
Study 22307494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 19358074 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School integrated into a multidisciplinary programme
Number of subjects: 0
Study 19358074 — intervention group
Group type: COMPARATOR
Intervention: Back School
Number of subjects: 0
Study 19358074 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School in an occupational setting
Number of subjects: 0
Study 17197463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 2.5 mg with fentanyl 15 microg
Number of subjects: 62
Study 17197463 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 2.5 mg with fentanyl 15 microg
Number of subjects: 62
Study 15502419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.75%)
Number of subjects: 50
Study 15502419 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2%)
Number of subjects: 50
Study 11470620 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-consultation (Mode C)
Number of subjects: 327
Study 11470620 — intervention group
Group type: COMPARATOR
Intervention: Teleradiology and telephone consultation (Mode B)
Number of subjects: 327
Study 11470620 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultation only (Mode A)
Number of subjects: 327
Study 9895184 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine to invigorate blood and relieve stasis
Number of subjects: 80
Study 9895184 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic drugs
Number of subjects: 80
Study 8023144 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal grill illusion (interlaced warm and cool bars)
Number of subjects: 0
Study 8023144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological recordings from ascending spinothalamic tract neurons
Number of subjects: 0
Study 8023144 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical verification of the model
Number of subjects: 0
Study 2557268 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker atenolol
Number of subjects: 9
Study 2557268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2557268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water stimulation
Number of subjects: 9
Study 2557268 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water stimulation
Number of subjects: 9
Study 2557268 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockade
Number of subjects: 9
Study 31228629 — intervention group
Group type: EXPERIMENTAL
Intervention: Auvi-Q
Number of subjects: 96
Study 31228629 — intervention group
Group type: COMPARATOR
Intervention: EpiPen Jr
Number of subjects: 96
Study 28706262 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 g/l of body water)
Number of subjects: 15
Study 28706262 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study 26495912 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil only
Number of subjects: 237
Study 26495912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tadalafil + Pentoxifylline
Number of subjects: 237
Study 22929394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training group (3 times a week for 12 weeks)
Number of subjects: 83
Study 22929394 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 83
Study 22128614 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids 2 g/day for at least 5 days before surgery and until hospital discharge
Number of subjects: 201
Study 22128614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no n‐3 polyunsaturated fatty acids)
Number of subjects: 201
Study 18384467 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 195
Study 17211567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of multiple insulin injections and oral repaglinide (1.5 mgr tid)
Number of subjects: 50
Study 12798824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 18
Study 12798824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 18
Study 12798824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11420773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol‐17 beta with cyclical dydrogesterone
Number of subjects: 595
Study 11420773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol‐17 beta with cyclical dydrogesterone
Number of subjects: 595
Study 11420773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study 9263561 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella infection during the first 20 weeks of gestation
Number of subjects: 22
Study 9263561 — intervention group
Group type: COMPARATOR
Intervention: Infants of women with varicella
Number of subjects: 22
Study 8325066 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled piretanide (12 mg)
Number of subjects: 10
Study 8325066 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled piretanide (24 mg)
Number of subjects: 10
Study 8325066 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled piretanide (48 mg)
Number of subjects: 10
Study 8325066 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10
Study 3792214 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 0
Study 3792214 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (all subjects simultaneously)
Number of subjects: 0
Study 3792214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31864157 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) for ≤ 4 cycles (group 1)
Number of subjects: 501
Study 31864157 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) for ≥ 5 cycles (group 2)
Number of subjects: 501
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Help-seeking from health professionals
Number of subjects: 274
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support
Number of subjects: 274
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Help-seeking from general practitioners
Number of subjects: 274
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Help-seeking from oncologist/treating clinician
Number of subjects: 274
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification as a lung cancer patient
Number of subjects: 274
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived legitimacy of discrimination
Number of subjects: 274
Study 29802652 — intervention group
Group type: EXPERIMENTAL
Intervention: Help-seeking behaviours
Number of subjects: 274
Study 27991894 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided IV busulfan (AUC of 6000 μM min)
Number of subjects: 218
Study 27991894 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose IV busulfan (130 mg/m2)
Number of subjects: 218
Study 25800362 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias modification
Number of subjects: 43
Study 25800362 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 43
Study 23887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalisation-based treatment (MBT)
Number of subjects: 0
Study 23887998 — intervention group
Group type: COMPARATOR
Intervention: Structured clinical management (SCM)
Number of subjects: 0
Study 21940527 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISION TACE with drug-eluting beads (DEB)
Number of subjects: 212
Study 21940527 — intervention group
Group type: COMPARATOR
Intervention: Conventional TACE
Number of subjects: 212
Study 18177513 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg/d
Number of subjects: 20
Study 18177513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16456680 — intervention group
Group type: EXPERIMENTAL
Intervention: G+MET (insulin glargine + metformin)
Number of subjects: 110
Study 16456680 — intervention group
Group type: COMPARATOR
Intervention: NPH+MET (NPH insulin + metformin)
Number of subjects: 110
Study 16456680 — intervention group
Group type: EXPERIMENTAL
Intervention: G+MET
Number of subjects: 110
Study 16456680 — intervention group
Group type: COMPARATOR
Intervention: NPH+MET
Number of subjects: 110
Study 15023878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice per week (RENAISSANCE)
Number of subjects: 2078
Study 15023878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg weekly (RECOVER)
Number of subjects: 2078
Study 15023878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (combined higher doses)
Number of subjects: 2078
Study 15023878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (RENAISSANCE)
Number of subjects: 2078
Study 15023878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (RECOVER)
Number of subjects: 2078
Study 15023878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (combined higher doses)
Number of subjects: 2078
Study 11477530 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwalk-like virus infection
Number of subjects: 775
Study 9286464 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly oleic sunflower oil (HOSO)
Number of subjects: 42
Study 9286464 — intervention group
Group type: COMPARATOR
Intervention: Palmolein
Number of subjects: 42
Study 8360240 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna Boot applied every 7 days
Number of subjects: 6
Study 8360240 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing and antihistamines
Number of subjects: 6
Study 3096364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 19